WuXi Biologics adds 4,000L bioreactors at fully single-use site

By Dan Stanton contact

- Last updated on GMT

The CMO says adding the single-use offering from ABEC will make the newly opened biomanufacturing site in China comparable to stainless steel for commercial mAb production.

Housing 14 times 2,000L single-use bioreactors provided by Thermo Fisher, WuXi Biologics describes its $150m facility​ in Wuxi City, Jiangsu, as the world’s largest mammalian cell culture manufacturing site using disposable systems.

But the firm is increasing capacity by installing the largest available single-use bioreactors at the site: 4,000L Custom Single Run (CSR) disposable bioreactors from ABEC. Through the configuration of six bioreactors together, the site will be able to offer commercial volumes of 24,000L in a single, disposable run.

According to Chris Chen, CEO of WuXi Biologics, the investment is not due to a specific client but rather future demand.

“This is a WuXi initiated development to potentially enable 24,000L run using disposables, making it comparable to large scale stainless,”​ he told this publication.

“Each batch can produce 4-20kg,”​ he continued, adding the systems will be operational by April 2019.

Bethlehem, Pennsylvania-headquartered ABEC spokesperson Susan Cooper-Curcio told this publication: "WuXi’s selection, as well as our activities with other customers, further validates the industry’s need for flexible and scalable solutions as customers look to transition single-use technology from R&D and clinical applications to cost-effective commercial manufacturing or approved products."

Smashing the plastic ceiling

The time-saving and reduced contamination risk benefits of single-use bioreactors are well documented, but a major criticism made by end-users – including Pfizer​​ and Janssen​​ – concerns their limited scale for commercial production, compared to the 15,000L, 20,000L and beyond capacity of stainless steel tanks.

2,000L is considered a ceiling for single-use bioreactor bags​ due to the significant pressure from the increased weight of the liquid medium in larger volume bags, coupled with the significant learning curve for an end-user to manage.

However, ABEC launched a 4,300L bioreactor (with 3,500L of working volume) in 2015​​ and the 4,900L system (with a 4,000L working volume) last year​.

According to the firm, these systems overcome the pressure issues due to “simple support structures at the lower ports.”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more